Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.
GE HealthCare And University Hospitals Enter 10-Year Strategic Collaboration To Contemporize Its Imaging Fleet And Implement Enterprise Digital Solutions To Help Improve Patient Care And Optimize Processes
Technology-powered collaboration aims to deliver AI-enabled devices and digital solutions at the enterprise level to increase clinical and operational efficiencies, drive workflow enhancements and improve patient
